Kenvue Inc. (NYSE:KVUE) Shares Sold by South Dakota Investment Council

South Dakota Investment Council decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 0.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 496,749 shares of the company’s stock after selling 4,100 shares during the period. South Dakota Investment Council’s holdings in Kenvue were worth $10,695,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Empirical Finance LLC bought a new position in Kenvue in the 3rd quarter worth about $336,000. UniSuper Management Pty Ltd bought a new position in Kenvue in the 3rd quarter worth about $35,544,000. Citizens Business Bank bought a new position in Kenvue in the 3rd quarter worth about $2,507,000. Fifth Third Bancorp grew its position in Kenvue by 35.3% in the 4th quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock worth $5,976,000 after purchasing an additional 72,435 shares during the last quarter. Finally, Clearbridge Investments LLC grew its position in Kenvue by 364.6% in the 3rd quarter. Clearbridge Investments LLC now owns 484,321 shares of the company’s stock worth $9,725,000 after purchasing an additional 380,071 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 0.8 %

NYSE:KVUE traded down $0.16 during trading hours on Wednesday, reaching $19.21. 14,660,907 shares of the company’s stock were exchanged, compared to its average volume of 16,625,646. Kenvue Inc. has a 12 month low of $17.82 and a 12 month high of $27.80. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. The business’s 50-day simple moving average is $19.84 and its two-hundred day simple moving average is $20.15.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. The firm had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm’s revenue was down 2.7% compared to the same quarter last year. Sell-side analysts predict that Kenvue Inc. will post 1.15 EPS for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were given a $0.20 dividend. The ex-dividend date of this dividend was Tuesday, February 13th. This represents a $0.80 annualized dividend and a dividend yield of 4.16%.

Analyst Ratings Changes

Several research analysts have commented on the stock. Sanford C. Bernstein assumed coverage on shares of Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price for the company. JPMorgan Chase & Co. decreased their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 9th. The Goldman Sachs Group initiated coverage on shares of Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price objective for the company. William Blair initiated coverage on shares of Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating for the company. Finally, Royal Bank of Canada decreased their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.